Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Patients With Heart Failure and Reduced Ejection Fraction: Randomized, Placebo-controlled, Parallel-group, Double-blind Trial

NCT07697833 is registered in ClinicalTrials.gov with National Institute of Cardiovascular Diseases, Pakistan as lead sponsor.

NCT NCT07697833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07697833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Patients With Heart Failure and Reduced Ejection Fraction: Randomized, Placebo-controlled, Parallel-group, Double-blind Trial
Lead sponsor
National Institute of Cardiovascular Diseases, Pakistan
Phase
Phase 4
Overall status
Not yet recruiting
Start date
July 15, 2026
Completion date
July 31, 2027
Enrollment
500 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with reduced ejection fraction (hfref)